The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...

Heart attacks are increasingly affecting people in their 40s due to poor lifestyle habits and chronic stress. Experts say the risk builds silently over years but can be reduced through simple ...

From cholesterol chemistry to muscle pain fears, this guide unpacks how statins work, who they help most, and why concerns ...

According to research done by the Ministry of Health, most deaths that have been recorded in the past few years were due to ...

Millions of adults are living with high cholesterol, increasing heart disease and stroke risk. Evidence suggests that eating ...

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients ...

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

Regular movement improves blood pressure control, supports healthy blood vessels, reduces inflammation and helps maintain healthy body weight.

The US Food and Drug Administration has approved the use of lerodalcibep (Lerochol) to reduce LDL cholesterol alongside ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...